Answers are grounded in this paper and cite their sources.
In the context of rising healthcare costs, increasing cancer incidence, and growing pressure on radiology services and workforce shortages, critical evaluation of [ 18 F]FDG PET/CT use in breast cancer patients is warranted. This study assessed the cost and workload implications of routine [ 18 F]FDG PET/CT in patients scheduled for preoperative systemic therapy (PST). We performed a retrospective real-world data analysis of patients scheduled for PST between 2011 and 2020 at our institute, all of whom underwent [ 18 F]FDG PET/CT prior to treatment. Breast cancer-related and non-breast cancer findings, subsequent diagnostic procedures, and final diagnoses were recorded and classified by clinical relevance. Scenario analyses evaluated the impact of de-escalating [ 18 F]FDG PET/CT use in selected patient groups. Among 1,330 patients, [ 18 F]FDG PET/CT resulted in 522 additional investigations and upstaging in 20% of patients. Total costs were €1,94 million and total workload 2,506 h, of which 24% was attributable to upstaged patients. Mean cost and workload per patient increased with clinical stage, while upstaging rates ranged from 6% (stage I) to 35% (stage III). Incidental, non-breast cancer findings were identified in 13% of patients, accounting for 7% of total diagnostic costs and workload. Omitting [ 18 F]FDG PET/CT in stages I-IIA could reduce estimated annual costs and workload by around 60%. Routine [ 18 F]FDG PET/CT in breast cancer patients undergoing PST is associated with substantial costs and workload, largely driven by findings without impact on treatment planning. In stage I-IIA disease, the limited clinical benefit may not justify routine use, supporting a more selective, value-based approach to pre-PST staging.
No takes yet. Share an insight, caveat, or question.
Gunster et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: